Inducing Hypermutability to Promote Anti-PD-1 Therapy Response.

ABSTRACT:

Summary

The lack of clinical activity from various immune-checkpoint blockade approaches in mismatch repair- proficient (MMRp) colorectal cancer has demonstrated a critical need for novel approaches. In this issue, Crisafulli and colleagues provide proof of concept for the induction of hypermutability through the use of temozolomide as a potential pathway for enabling a productive anti-PD-1 immune response in MMRp colorectal cancer. See related article by Crisafulli et al., p. 1656 (1) .

SUBMITTER: Willis JA 

PROVIDER: S-EPMC10373529 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature